Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Lung Cancer
Primary: Objective Response Rate (OR) Where OR=CR+PR: Number of Participants With Responses of Complete Response (CR) and Partial Response (PR) — 3 Participants
Phase 2 N=86 Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Advanced Breast Cancer
Primary: Number of Participants With Stomatitis Grade ≥ 2 — 2; 83; 1 Participants — p=<0.001
Phase 2 N=40 An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 100; 100 Percentage of Participants
Phase 2 N=54 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Brain Tumors · Nervous System Tumors · Cognition Disorders
Primary: Retention — 85; 75 percentage of participants
Phase 2 N=47 Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
Colorectal Neoplasms
Primary: Progression Free Survival (Arm A) — 0.946; 0.892; 0.739; 0.685 proportion of patients with PFS
Phase 2 N=124 A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Nonseasonal
Primary: Average Total Nasal Symptom Score (TNSS) During Environmental Exposure Chamber (EEC) Challenge Session at Week 24 — 3.83; 5.47; 7.45 Score on a Scale — p=<0.001
Phase 2 N=25 OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation
Malaria
Primary: Minimum Inhibitory Concentration (MIC) and Minimum Parasiticidal Concentration (MPC) — 2.4; 4.1; 77; 319 ng/Ml
Phase 2 N=88 Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 30.92; 30.32; 33.43; 32.76 T score
Phase 2 N=70 BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Mean Change From Baseline in 7-Point Glucose Monitoring (7-PGM) at Day 7 — -16.52; -19.01; -17.29; -23.40 mg/dL
Phase 2 N=63 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Marginal Zone Lymphoma · B-cell Lymphoma
Primary: ORR (Overall Response Rate) — 46 Percentage of Participants
Phase 2 N=50 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029
Phase 2 N=323 Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -1.82; -1.64 percentage of hemoglobin — p=0.0130
Phase 2 N=88 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Leukemia
Primary: Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA) — 0; 0; 0; 0 participants
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24